ClinicalTrials.gg
CompletedNCT03682705Updated May 3, 2021Results posted

A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis

A Phase 2 interventional study of Elsubrutinib and Upadacitinib in Rheumatoid Arthritis (RA), sponsored by AbbVie. Completed at 115 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-03.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
242
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing upadacitinib in Arthritis, Rheumatoid — 3 open to participants now, 3 under way, none of them phase 3. upadacitinib · Arthritis, Rheumatoid.

Enrollment
13th of 19
242 · median 300
Started
2018
with 1 other
Phase 2
7 of 19
2 open now
Registered
11th of 19
by date
Lead sponsor
13 of 19
AbbVie

Among the 19 studies testing upadacitinib in Arthritis, Rheumatoid, this one is the 13th largest by enrollment, is one of 2 that started in 2018, is one of 7 in phase 2, and was the 11th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 19 studies testing upadacitinib in Arthritis, Rheumatoid are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing upadacitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This was a phase 2 study to evaluate the safety and efficacy of elsubrutinib (ELS) and ABBV-599 (ELS plus upadacitinib [UPA]) vs placebo on a background of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) for the treatment of signs and symptoms of rheumatoid arthritis (RA) at 12 weeks in biological disease-modifying anti-rheumatic drugs (bDMARD)-inadequate response (bDMARD-IR) or bDMARD-intolerant participants with moderately to severely active RA and to define optimal dose for further development.

Read the detailed description

This was a 12-week, randomized, double-blind, parallel-group, Phase 2, dose exploratory, multicenter study. Participants who met eligibility criteria were randomized in a 3:2:2:2:2:1 ratio to 1 of 6 treatment groups: ABBV-599 [UPA 15 mg/ELS 60 mg]); ELS 60 mg/UPA placebo; ELS 20 mg/UPA placebo; ELS 5 mg/UPA placebo; UPA 15 mg/ELS placebo; and ELS placebo/UPA placebo. The study included a 35-day maximum screening period and a 12-week treatment period with 30-day follow-up.

03

Conditions studied

  • Rheumatoid Arthritis (RA)

Keywords

  • Elsubrutinib
  • ABBV-105
  • Upadacitinib
  • ABBV-599
  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of rheumatoid arthritis (RA) for ≥ 3 months based on the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for RA
  • Participant meets the following minimum disease activity criteria:

    • ≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits
    • High-sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L (central lab) at Screening Visit
  • Participants must have been treated for ≥ 3 months with ≥ 1 biologic disease-modifying anti-rheumatic drug (bDMARD) therapy but continue to exhibit active RA or had to discontinue due to intolerability or toxicity, irrespective of treatment duration
  • Participants must have been receiving conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) therapy ≥ 3 months and on a stable dose for ≥ 4 weeks prior to the first dose of study drug
  • Participants must have discontinued all bDMARDs prior to the first dose of study drug

Exclusion criteria

Exclusion Criteria:

  • Participant has prior exposure to any Janus Kinase (JAK) inhibitor for greater than 2 weeks (including but not limited to upadacitinib, tofacitinib, baricitinib, and filgotinib). A of ≥ 30 days is required for any JAK inhibitor prior to the first dose of study drug.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
242 participants (actual)

Study arms

  • Placebo comparator
    ELS placebo/UPA placebo

    Placebo capsule for elsubrutinib once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks

    Drug: Placebo for elsubrutinib · Drug: Placebo for upadacitinib

  • Experimental
    UPA 15 mg/ELS 60 mg

    15 mg film-coated upadacitinib tablet once a day by mouth for 12 weeks; 60 mg elsubrutinib capsule once a day by mouth for 12 weeks

    Drug: Elsubrutinib · Drug: Upadacitinib

  • Experimental
    ELS 60 mg/UPA placebo

    60 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks

    Drug: Elsubrutinib · Drug: Placebo for upadacitinib

  • Experimental
    ELS 20 mg/UPA placebo

    20 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks

    Drug: Elsubrutinib · Drug: Placebo for upadacitinib

  • Experimental
    ELS 5 mg/UPA placebo

    5 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks

    Drug: Elsubrutinib · Drug: Placebo for upadacitinib

  • Experimental
    UPA 15 mg/ELS placebo

    15 mg film-coated upadacitinib tablet once a day by mouth for 12 weeks; placebo capsule for elsubrutinib once a day by mouth for 12 weeks

    Drug: Upadacitinib · Drug: Placebo for elsubrutinib

Interventions

  • Elsubrutinib capsule will be administered orally.

    Also known as: ABBV-105

  • Upadacitinib tablet will be administered orally.

    Also known as: ABT-494

  • DrugPlacebo for elsubrutinib

    Placebo capsule for elsubrutinib will be administered orally.

  • DrugPlacebo for upadacitinib

    Placebo tablet for upadacitinib will be administered orally.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) at Week 12

    The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline indicates improvement in disease activity.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline in Clinical Disease Activity Index (CDAI)

    The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. A negative change from baseline indicates improvement in disease activity.

    Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12

  2. Change From Baseline in Simplified Disease Activity Index (SDAI)

    The SDAI is a validated measure of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, global disease activity assessed by the participant on a visual analogue scale from 0 to 10 (cm), global disease activity assessed by an investigator on a visual analogue scale from 0 to 10 (cm), and serum levels of C-reactive protein (CRP; mg/dL) were included in the SDAI score. Scores on the SDAI range from 0 to 86.with higher scores indicating higher disease activity. A negative change from baseline indicates improvement in disease activity.

    Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12

  3. Percentage of Participants Achieving Clinical Remission (CR) Based on Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) at Week 12

    The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Clinical remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than 2.6.

    Time frame: At Week 12

  4. Percentage of Participants Achieving Low Disease Activity (LDA) Based on Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) at Week 12

    The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Low Disease Activity (LDA) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than or equal to 3.2.

    Time frame: At Week 12

  5. Percentage of Participants Achieving Low Disease Activity (LDA) Based on Clinical Disease Activity Index (CDAI) Criteria

    The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Low Disease Activity (LDA) based on CDAI is defined as achieving a CDAI of less than or equal to 10.

    Time frame: Week 2, Week 4, Week 8, and Week 12

  6. Percentage of Participants Achieving Complete Remission (CR) Based on Clinical Disease Activity Index (CDAI) Criteria

    The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Complete Remission (CR) based on CDAI is defined as achieving a CDAI of less than or equal to 2.8.

    Time frame: Week 2, Week 4, Week 8, and Week 12

  7. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response

    Participants who met the following 3 conditions for improvement from baseline were classified as meeting the American College of Rheumatology 20% response (ACR20) criteria: 1. ≥ 20% improvement in 68-tender joint count 2. ≥ 20% improvement in 66-swollen joint count and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)

    Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12

  8. Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response

    Participants who met the following 3 conditions for improvement from baseline were classified as meeting the American College of Rheumatology 50% response (ACR50) criteria: 1. ≥ 50% improvement in 68-tender joint count 2. ≥ 50% improvement in 66-swollen joint count and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)

    Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12

  9. Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response

    Participants who met the following 3 conditions for improvement from baseline were classified as meeting the American College of Rheumatology 70% response (ACR70) criteria: 1. ≥ 70% improvement in 68-tender joint count 2. ≥ 70% improvement in 66-swollen joint count and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)

    Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12

  10. Change From Baseline in Tender Joint Count 68 (TJC68)

    Sixty-eight joints were assessed for tenderness by physical examination. Pain or tenderness of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with tenderness) to 68 (worst possible score/68 joints with tenderness). Negative values indicate improvement from baseline.

    Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12

  11. Change From Baseline in Swollen Joint Count 66 (SJC66)

    Sixty-six joints were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with swelling) to 66 (worst possible score/66 joints with swelling). Negative values indicate improvement from baseline.

    Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12

  12. Change From Baseline in Participant's Assessment of Pain (Visual Analog Scale [VAS])

    Participants rated their pain on a visual analogue scale (VAS) of 0 to 100 (mm), with 0 representing no pain and 100 representing the worst possible pain. Negative values indicate improvement from baseline.

    Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12

  13. Change From Baseline in Patient's Global Assessment of Disease Activity (PGA)

    Participants rated their disease activity for the past 24 hours using a Patient's Global Assessment of Disease Activity Global visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.

    Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12

  14. Change From Baseline in Physician's Global Assessment of Disease Activity (PhGA)

    The physician assessed a participant's disease activity at the time of the visit using a Physician's Global Assessment of Disease visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.

    Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12

  15. Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from baseline in the overall score indicates improvement.

    Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12

  16. Change From Baseline in High-Sensitivity C-reactive Protein (hsCRP)

    C-reactive protein is a blood test marker for inflammation in the body, and levels rise in response to inflammation. A negative change from baseline in indicates improvement.

    Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12

  17. Change From Baseline in Disease Activity Score 28 C-reactive Protein [DAS28-CRP])

    The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline indicates improvement in disease activity.

    Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12

  18. Change From Baseline in Disease Activity Score 28 Erythrocyte Sedimentation Rate (DAS28- ESR)

    The DAS28-ESR is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR; mm/hour), and the participant's assessment of global disease activity (on a visual analog scale \[VAS\] from 0 to 100 mm) are included in the DAS28 -ESR score. Scores on the DAS28-ESR range from 0 to 10; higher scores indicate more disease activity.

    Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12

  19. Change From Baseline in Morning Stiffness Severity

    Morning stiffness severity was assessed by a numeric rating-scale (NRS). Participants rated the severity of morning stiffness during the past week from 0 to 10 with 0 representing "not severe" and 10 "very severe". Negative values indicate improvement from baseline.

    Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12

  20. Percentage of Participants Achieving Minimal Clinically Important Difference (MCID) in Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. The minimal clinically important difference (MCID) in HAQ-DI is defined as change from Baseline ≤ -0.22 for rheumatoid arthritis.

    Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12

  21. Percentage of Participants Achieving American College of Rheumatology/European League Against Rheumatism (EULAR) Boolean Remission

    The EULAR Boolean-based definition of remission is as follows: at any time point, a participant must satisfy all of the following: tender joint count ≤1, swollen joint count ≤1, C-reactive protein ≤1 mg/dl and Patient Global Assessment (PGA) ≤1 (on a 0-10 scale).

    Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12

07

Results

Posted May 3, 2021

Participant flow

Participant flow — Overall Study
MilestoneELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Started196241394140
Completed175838343538
Not completed243562
Withdrew: Adverse event111011
Withdrew: Withdrawal by subject132401
Withdrew: Other, not specified000120
Withdrew: Lost to follow-up000030

Outcome measures

PrimaryChange From Baseline in Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) at Week 12

The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline indicates improvement in disease activity.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) at Week 12
units on a scaleELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Change From Baseline in Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) at Week 12-1.12 (-1.64 to -0.60)-2.56 (-2.86 to -2.26)-1.52 (-1.89 to -1.15)-1.32 (-1.71 to -0.93)-1.33 (-1.70 to -0.97)-2.87 (-3.23 to -2.51)
Statistical analysis
  • ELS Placebo/UPA Placebo vs UPA 15 mg/ELS 60 mg · t-test, 2 sided · p = <0.001 · Ls mean difference: -1.44 · 90% CI -2.03 to -0.85
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI)

The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. A negative change from baseline indicates improvement in disease activity.

Time frame:
Baseline, Week 2, Week 4, Week 8, and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI)
units on a scaleELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Week 2-6.08 (-10.48 to -1.67)-16.00 (-18.53 to -13.47)-8.95 (-11.99 to -5.91)-7.36 (-10.44 to -4.27)-8.38 (-11.48 to -5.28)-14.03 (-17.04 to -11.02)
Week 4-11.60 (-16.38 to -6.82)-20.24 (-22.97 to -17.50)-11.67 (-15.01 to -8.34)-10.10 (-13.50 to -6.70)-12.90 (-16.22 to -9.58)-20.30 (-23.57 to -17.03)
Week 8-12.46 (-17.52 to -7.40)-24.95 (-27.86 to -22.05)-15.07 (-18.65 to -11.49)-17.10 (-20.83 to -13.38)-14.84 (-18.42 to -11.26)-23.72 (-27.20 to -20.24)
Week 12-14.57 (-19.77 to -9.36)-27.00 (-30.05 to -23.95)-17.50 (-21.22 to -13.78)-16.70 (-20.62 to -12.78)-16.51 (-20.27 to -12.75)-28.85 (-32.48 to -25.21)
SecondaryChange From Baseline in Simplified Disease Activity Index (SDAI)

The SDAI is a validated measure of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, global disease activity assessed by the participant on a visual analogue scale from 0 to 10 (cm), global disease activity assessed by an investigator on a visual analogue scale from 0 to 10 (cm), and serum levels of C-reactive protein (CRP; mg/dL) were included in the SDAI score. Scores on the SDAI range from 0 to 86.with higher scores indicating higher disease activity. A negative change from baseline indicates improvement in disease activity.

Time frame:
Baseline, Week 2, Week 4, Week 8, and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Simplified Disease Activity Index (SDAI)
units on a scaleELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Week 2-6.17 (-10.67 to -1.67)-17.01 (-19.60 to -14.43)-8.79 (-11.89 to -5.68)-7.42 (-10.57 to -4.26)-8.54 (-11.71 to -5.38)-15.30 (-18.37 to -12.22)
Week 4-11.80 (-16.67 to -6.93)-21.24 (-24.02 to -18.45)-11.46 (-14.85 to -8.06)-10.15 (-13.61 to -6.68)-12.87 (-16.25 to -9.49)-21.59 (-24.92 to -18.26)
Week 8-12.15 (-17.35 to -6.95)-25.96 (-28.95 to -22.98)-15.26 (-18.94 to -11.57)-17.32 (-21.17 to -13.46)-15.21 (-18.89 to -11.53)-25.07 (-28.65 to -21.49)
Week 12-14.44 (-19.84 to -9.04)-28.06 (-31.22 to -24.89)-18.01 (-21.86 to -14.15)-17.12 (-21.20 to -13.05)-16.73 (-20.65 to -12.81)-29.65 (-33.42 to -25.88)
SecondaryPercentage of Participants Achieving Clinical Remission (CR) Based on Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) at Week 12

The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Clinical remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than 2.6.

Time frame:
At Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Remission (CR) Based on Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) at Week 12
percentage of participantsELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Percentage of Participants Achieving Clinical Remission (CR) Based on Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) at Week 1210.5 (3.55 to 27.35)32.3 (23.41 to 42.59)19.5 (11.36 to 31.44)7.7 (3.12 to 17.76)9.8 (4.46 to 20.04)42.5 (30.52 to 55.43)
SecondaryPercentage of Participants Achieving Low Disease Activity (LDA) Based on Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) at Week 12

The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Low Disease Activity (LDA) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than or equal to 3.2.

Time frame:
At Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Low Disease Activity (LDA) Based on Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) at Week 12
percentage of participantsELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Percentage of Participants Achieving Low Disease Activity (LDA) Based on Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) at Week 1221.1 (9.82 to 39.50)41.9 (32.18 to 52.37)22.0 (13.24 to 34.13)10.3 (4.69 to 20.98)14.6 (7.76 to 25.89)55.0 (42.16 to 67.21)
SecondaryPercentage of Participants Achieving Low Disease Activity (LDA) Based on Clinical Disease Activity Index (CDAI) Criteria

The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Low Disease Activity (LDA) based on CDAI is defined as achieving a CDAI of less than or equal to 10.

Time frame:
Week 2, Week 4, Week 8, and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Low Disease Activity (LDA) Based on Clinical Disease Activity Index (CDAI) Criteria
percentage of participantsELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Week 210.5 (3.55 to 27.35)16.1 (9.89 to 25.20)9.8 (4.46 to 20.04)0 (0.00 to 6.49)2.4 (0.55 to 10.22)12.5 (6.22 to 23.53)
Week 410.5 (3.55 to 27.35)29.0 (20.59 to 39.23)12.2 (6.06 to 23.01)7.7 (3.12 to 17.76)12.2 (6.06 to 23.01)22.5 (13.59 to 34.90)
Week 85.3 (1.18 to 20.50)46.8 (36.71 to 57.11)17.1 (9.53 to 28.69)20.5 (11.96 to 32.89)24.4 (15.17 to 36.78)35.0 (23.91 to 47.99)
Week 1226.3 (13.44 to 45.09)37.1 (27.74 to 47.53)34.1 (23.29 to 46.97)17.9 (10.03 to 30.02)17.1 (9.53 to 28.69)57.5 (44.57 to 69.48)
SecondaryPercentage of Participants Achieving Complete Remission (CR) Based on Clinical Disease Activity Index (CDAI) Criteria

The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Complete Remission (CR) based on CDAI is defined as achieving a CDAI of less than or equal to 2.8.

Time frame:
Week 2, Week 4, Week 8, and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Complete Remission (CR) Based on Clinical Disease Activity Index (CDAI) Criteria
percentage of participantsELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Week 20 (0.00 to 12.46)3.2 (1.07 to 9.29)0 (0.00 to 6.19)0 (0.00 to 6.49)0 (0.00 to 6.19)0 (0.00 to 6.34)
Week 40 (0.00 to 12.46)6.5 (2.93 to 13.62)2.4 (0.55 to 10.22)2.6 (0.57 to 10.71)0 (0.00 to 6.19)2.5 (0.56 to 10.46)
Week 80 (0.00 to 12.46)12.9 (7.43 to 21.48)7.3 (2.96 to 16.96)2.6 (0.57 to 10.71)2.4 (0.55 to 10.22)12.5 (6.22 to 23.53)
Week 125.3 (1.18 to 20.50)14.5 (8.65 to 23.35)7.3 (2.96 to 16.96)5.1 (1.71 to 14.37)0 (0.00 to 6.19)15.0 (7.96 to 26.47)
SecondaryPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response

Participants who met the following 3 conditions for improvement from baseline were classified as meeting the American College of Rheumatology 20% response (ACR20) criteria: 1. ≥ 20% improvement in 68-tender joint count 2. ≥ 20% improvement in 66-swollen joint count and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)

Time frame:
Baseline, Week 2, Week 4, Week 8, and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
percentage of participantsELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Week 221.1 (9.82 to 39.50)45.2 (35.19 to 55.54)24.4 (15.17 to 36.78)12.8 (6.38 to 24.08)14.6 (7.76 to 25.89)52.5 (39.77 to 64.91)
Week 442.1 (25.63 to 60.55)51.6 (41.33 to 61.76)29.3 (19.16 to 41.94)23.1 (13.95 to 35.70)22.0 (13.24 to 34.13)55.0 (42.16 to 67.21)
Week 836.8 (21.37 to 55.59)64.5 (54.11 to 73.71)39.0 (27.55 to 51.86)30.8 (20.20 to 43.84)39.0 (27.55 to 51.86)67.5 (54.55 to 78.23)
Week 1247.4 (30.07 to 65.33)64.5 (54.11 to 73.71)41.5 (29.72 to 54.26)30.8 (20.20 to 43.84)34.1 (23.29 to 46.97)72.5 (59.75 to 82.40)
SecondaryPercentage of Participants With an American College of Rheumatology 50% (ACR50) Response

Participants who met the following 3 conditions for improvement from baseline were classified as meeting the American College of Rheumatology 50% response (ACR50) criteria: 1. ≥ 50% improvement in 68-tender joint count 2. ≥ 50% improvement in 66-swollen joint count and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)

Time frame:
Baseline, Week 2, Week 4, Week 8, and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
percentage of participantsELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Week 20 (0.00 to 12.46)16.1 (9.89 to 25.20)4.9 (1.63 to 13.71)0 (0.00 to 6.49)0 (0.00 to 6.19)12.5 (6.22 to 23.53)
Week 410.5 (3.55 to 27.35)19.4 (12.46 to 28.82)17.1 (9.53 to 28.69)2.6 (0.57 to 10.71)4.9 (1.63 to 13.71)30.0 (19.66 to 42.87)
Week 85.3 (1.18 to 20.50)41.9 (32.18 to 52.37)19.5 (11.36 to 31.44)12.8 (6.38 to 24.08)7.3 (2.96 to 16.96)40.0 (28.29 to 52.98)
Week 1221.1 (9.82 to 39.50)45.2 (35.19 to 55.54)29.3 (19.16 to 41.94)12.8 (6.38 to 24.08)17.1 (9.53 to 28.69)47.5 (35.09 to 60.23)
SecondaryPercentage of Participants With an American College of Rheumatology 70% (ACR70) Response

Participants who met the following 3 conditions for improvement from baseline were classified as meeting the American College of Rheumatology 70% response (ACR70) criteria: 1. ≥ 70% improvement in 68-tender joint count 2. ≥ 70% improvement in 66-swollen joint count and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)

Time frame:
Baseline, Week 2, Week 4, Week 8, and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
percentage of participantsELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Week 20 (0.00 to 12.46)8.1 (3.98 to 15.66)2.4 (0.55 to 10.22)0 (0.00 to 6.49)0 (0.00 to 6.19)0 (0.00 to 6.34)
Week 40 (0.00 to 12.46)9.7 (5.09 to 17.64)4.9 (1.63 to 13.71)2.6 (0.57 to 10.71)0 (0.00 to 6.19)15.0 (7.96 to 26.47)
Week 80 (0.00 to 12.46)17.7 (11.16 to 27.02)4.9 (1.63 to 13.71)2.6 (0.57 to 10.71)0 (0.00 to 6.19)25.0 (15.57 to 37.60)
Week 1215.8 (6.49 to 33.62)25.8 (17.81 to 35.82)14.6 (7.76 to 25.89)5.1 (1.71 to 14.37)9.8 (4.46 to 20.04)27.5 (17.60 to 40.25)
SecondaryChange From Baseline in Tender Joint Count 68 (TJC68)

Sixty-eight joints were assessed for tenderness by physical examination. Pain or tenderness of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with tenderness) to 68 (worst possible score/68 joints with tenderness). Negative values indicate improvement from baseline.

Time frame:
Baseline, Week 2, Week 4, Week 8, and Week 12
Reported as:
Least squares mean · tender joint counts
Change From Baseline in Tender Joint Count 68 (TJC68)
tender joint countsELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Week 2-2.47 (-6.10 to 1.16)-8.42 (-10.53 to -6.31)-3.65 (-6.23 to -1.07)-3.86 (-6.46 to -1.26)-4.88 (-7.43 to -2.33)-8.57 (-11.09 to -6.05)
Week 4-9.21 (-13.08 to -5.34)-11.86 (-14.10 to -9.62)-5.16 (-7.93 to -2.39)-5.39 (-8.18 to -2.60)-8.08 (-10.77 to -5.39)-12.76 (-15.46 to -10.06)
Week 8-8.82 (-12.85 to -4.79)-15.44 (-17.75 to -13.12)-8.43 (-11.31 to -5.55)-10.83 (-13.78 to -7.88)-9.08 (-11.88 to -6.27)-14.76 (-17.56 to -11.97)
Week 12-8.47 (-12.81 to -4.12)-16.33 (-18.84 to -13.83)-9.14 (-12.23 to -6.05)-9.33 (-12.55 to -6.12)-12.58 (-15.64 to -9.52)-17.56 (-20.58 to -14.53)
SecondaryChange From Baseline in Swollen Joint Count 66 (SJC66)

Sixty-six joints were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with swelling) to 66 (worst possible score/66 joints with swelling). Negative values indicate improvement from baseline.

Time frame:
Baseline, Week 2, Week 4, Week 8, and Week 12
Reported as:
Least squares mean · swollen joint counts
Change From Baseline in Swollen Joint Count 66 (SJC66)
swollen joint countsELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Week 2-3.12 (-5.20 to -1.05)-6.06 (-7.26 to -4.86)-3.61 (-5.08 to -2.14)-3.30 (-4.78 to -1.82)-4.13 (-5.60 to -2.67)-6.02 (-7.46 to -4.58)
Week 4-4.70 (-6.92 to -2.49)-7.96 (-9.24 to -6.68)-5.11 (-6.69 to -3.53)-4.67 (-6.27 to -3.07)-6.05 (-7.60 to -4.51)-8.81 (-10.35 to -7.26)
Week 8-4.32 (-6.57 to -2.06)-10.28 (-11.57 to -8.99)-6.15 (-7.77 to -4.54)-8.08 (-9.74 to -6.42)-7.58 (-9.15 to -6.00)-10.11 (-11.68 to -8.55)
Week 12-5.58 (-8.05 to -3.11)-10.86 (-12.29 to -9.44)-6.68 (-8.44 to -4.92)-7.85 (-9.70 to -6.01)-8.59 (-10.35 to -6.83)-11.14 (-12.86 to -9.42)
SecondaryChange From Baseline in Participant's Assessment of Pain (Visual Analog Scale [VAS])

Participants rated their pain on a visual analogue scale (VAS) of 0 to 100 (mm), with 0 representing no pain and 100 representing the worst possible pain. Negative values indicate improvement from baseline.

Time frame:
Baseline, Week 2, Week 4, Week 8, and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Participant's Assessment of Pain (Visual Analog Scale [VAS])
units on a scaleELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Week 2-14.97 (-22.80 to -7.14)-24.02 (-28.63 to -19.41)-10.22 (-15.81 to -4.63)-8.78 (-14.49 to -3.07)-7.61 (-13.12 to -2.11)-15.99 (-21.49 to -10.48)
Week 4-20.87 (-29.60 to -12.14)-28.17 (-33.28 to -23.07)-12.95 (-19.27 to -6.63)-8.41 (-14.85 to -1.97)-9.91 (-15.93 to -3.88)-25.58 (-31.69 to -19.48)
Week 8-16.21 (-25.97 to -6.45)-31.86 (-37.50 to -26.22)-20.92 (-27.96 to -13.88)-11.12 (-18.46 to -3.79)-13.90 (-20.64 to -7.16)-30.70 (-37.47 to -23.92)
Week 12-23.37 (-33.74 to -13.01)-32.27 (-38.32 to -26.23)-19.52 (-26.97 to -12.06)-10.46 (-18.38 to -2.55)-17.84 (-25.13 to -10.55)-38.34 (-45.57 to -31.12)
SecondaryChange From Baseline in Patient's Global Assessment of Disease Activity (PGA)

Participants rated their disease activity for the past 24 hours using a Patient's Global Assessment of Disease Activity Global visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.

Time frame:
Baseline, Week 2, Week 4, Week 8, and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Patient's Global Assessment of Disease Activity (PGA)
units on a scaleELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Week 2-11.87 (-20.12 to -3.63)-23.44 (-28.31 to -18.57)-11.16 (-17.07 to -5.25)-6.47 (-12.51 to -0.44)-5.95 (-11.76 to -0.14)-14.76 (-20.56 to -8.95)
Week 4-20.93 (-29.91 to -11.94)-25.97 (-31.24 to -20.70)-12.79 (-19.32 to -6.26)-7.15 (-13.79 to -0.50)-8.73 (-14.94 to -2.51)-23.02 (-29.31 to -16.73)
Week 8-15.14 (-25.37 to -4.91)-28.05 (-33.97 to -22.13)-17.25 (-24.65 to -9.84)-6.27 (-14.00 to 1.45)-14.25 (-21.34 to -7.17)-26.79 (-33.90 to -19.69)
Week 12-19.55 (-30.15 to -8.95)-30.52 (-36.72 to -24.32)-19.47 (-27.13 to -11.81)-8.45 (-16.58 to -0.33)-16.40 (-23.89 to -8.92)-33.53 (-40.94 to -26.13)
SecondaryChange From Baseline in Physician's Global Assessment of Disease Activity (PhGA)

The physician assessed a participant's disease activity at the time of the visit using a Physician's Global Assessment of Disease visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.

Time frame:
Baseline, Week 2, Week 4, Week 8, and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Physician's Global Assessment of Disease Activity (PhGA)
units on a scaleELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Week 2-16.31 (-24.67 to -7.96)-22.35 (-27.10 to -17.60)-19.01 (-24.74 to -13.27)-16.12 (-21.97 to -10.26)-11.64 (-17.44 to -5.84)-24.71 (-30.37 to -19.05)
Week 4-25.20 (-33.52 to -16.89)-33.54 (-38.26 to -28.82)-25.33 (-31.11 to -19.55)-19.59 (-25.49 to -13.69)-18.31 (-24.05 to -12.56)-34.17 (-39.86 to -28.49)
Week 8-24.47 (-32.71 to -16.22)-40.00 (-44.71 to -35.29)-30.06 (-35.91 to -24.22)-33.93 (-39.99 to -27.87)-25.21 (-31.03 to -19.40)-41.02 (-46.69 to -35.36)
Week 12-23.19 (-31.69 to -14.69)-46.98 (-52.00 to -41.96)-30.15 (-36.28 to -24.03)-31.68 (-38.19 to -25.18)-24.55 (-30.75 to -18.36)-50.89 (-56.87 to -44.91)
SecondaryChange From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from baseline in the overall score indicates improvement.

Time frame:
Baseline, Week 2, Week 4, Week 8, and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)
units on a scaleELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Week 2-0.22 (-0.37 to -0.06)-0.34 (-0.43 to -0.25)-0.13 (-0.24 to -0.02)-0.06 (-0.17 to 0.05)-0.16 (-0.27 to -0.05)-0.22 (-0.33 to -0.11)
Week 4-0.36 (-0.53 to -0.18)-0.39 (-0.49 to -0.29)-0.11 (-0.23 to 0.02)-0.14 (-0.27 to -0.02)-0.21 (-0.33 to -0.09)-0.33 (-0.45 to -0.20)
Week 8-0.24 (-0.44 to -0.05)-0.47 (-0.59 to -0.36)-0.29 (-0.43 to -0.15)-0.15 (-0.30 to -0.00)-0.15 (-0.29 to -0.02)-0.47 (-0.61 to -0.33)
Week 12-0.30 (-0.52 to -0.08)-0.52 (-0.65 to -0.39)-0.31 (-0.46 to -0.15)-0.12 (-0.28 to 0.05)-0.18 (-0.33 to -0.03)-0.54 (-0.70 to -0.39)
SecondaryChange From Baseline in High-Sensitivity C-reactive Protein (hsCRP)

C-reactive protein is a blood test marker for inflammation in the body, and levels rise in response to inflammation. A negative change from baseline in indicates improvement.

Time frame:
Baseline, Week 2, Week 4, Week 8, and Week 12
Reported as:
Least squares mean · mg/L
Change From Baseline in High-Sensitivity C-reactive Protein (hsCRP)
mg/LELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Week 2-0.51 (-4.82 to 3.81)-9.29 (-11.79 to -6.80)2.26 (-0.81 to 5.33)-0.34 (-3.43 to 2.74)-0.72 (-3.74 to 2.30)-12.27 (-15.26 to -9.27)
Week 41.54 (-3.72 to 6.79)-10.08 (-13.08 to -7.08)2.71 (-1.05 to 6.46)-0.78 (-4.58 to 3.02)0.72 (-2.91 to 4.35)-12.59 (-16.27 to -8.92)
Week 83.23 (-1.56 to 8.03)-9.97 (-12.70 to -7.24)-1.39 (-4.83 to 2.05)-2.58 (-6.15 to 1.00)-2.93 (-6.26 to 0.39)-13.13 (-16.46 to -9.81)
Week 121.45 (-5.10 to 8.00)-10.95 (-14.73 to -7.18)-4.58 (-9.26 to 0.09)-5.78 (-10.77 to -0.78)-0.81 (-5.58 to 3.97)-7.44 (-12.03 to -2.86)
SecondaryChange From Baseline in Disease Activity Score 28 C-reactive Protein [DAS28-CRP])

The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline indicates improvement in disease activity.

Time frame:
Baseline, Week 2, Week 4, Week 8, and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Disease Activity Score 28 C-reactive Protein [DAS28-CRP])
units on a scaleELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Week 2-0.46 (-0.83 to -0.10)-1.53 (-1.75 to -1.31)-0.63 (-0.89 to -0.36)-0.44 (-0.71 to -0.18)-0.56 (-0.82 to -0.30)-1.43 (-1.69 to -1.17)
Week 4-0.90 (-1.33 to -0.47)-1.96 (-2.21 to -1.71)-0.87 (-1.18 to -0.56)-0.68 (-1.00 to -0.36)-0.82 (-1.11 to -0.52)-1.98 (-2.28 to -1.67)
Week 8-0.78 (-1.27 to -0.29)-2.40 (-2.68 to -2.11)-1.21 (-1.56 to -0.86)-1.24 (-1.61 to -0.87)-1.11 (-1.45 to -0.77)-2.34 (-2.68 to -2.00)
Week 12-1.12 (-1.64 to -0.60)-2.56 (-2.86 to -2.26)-1.52 (-1.89 to -1.15)-1.32 (-1.71 to -0.93)-1.33 (-1.70 to -0.97)-2.87 (-3.23 to -2.51)
SecondaryChange From Baseline in Disease Activity Score 28 Erythrocyte Sedimentation Rate (DAS28- ESR)

The DAS28-ESR is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR; mm/hour), and the participant's assessment of global disease activity (on a visual analog scale \[VAS\] from 0 to 100 mm) are included in the DAS28 -ESR score. Scores on the DAS28-ESR range from 0 to 10; higher scores indicate more disease activity.

Time frame:
Baseline, Week 2, Week 4, Week 8, and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Disease Activity Score 28 Erythrocyte Sedimentation Rate (DAS28- ESR)
units on a scaleELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Week 2-0.46 (-0.82 to -0.09)-1.48 (-1.69 to -1.26)-0.52 (-0.79 to -0.26)-0.46 (-0.74 to -0.19)-0.57 (-0.83 to -0.32)-1.32 (-1.58 to -1.06)
Week 4-0.86 (-1.30 to -0.43)-1.93 (-2.19 to -1.68)-0.79 (-1.11 to -0.48)-0.59 (-0.91 to -0.26)-0.92 (-1.23 to -0.62)-1.90 (-2.20 to -1.59)
Week 8-0.80 (-1.29 to -0.31)-2.41 (-2.69 to -2.12)-1.07 (-1.42 to -0.71)-1.15 (-1.52 to -0.78)-1.20 (-1.54 to -0.86)-2.31 (-2.65 to -1.97)
Week 12-1.18 (-1.71 to -0.64)-2.53 (-2.84 to -2.22)-1.41 (-1.80 to -1.03)-1.24 (-1.65 to -0.83)-1.44 (-1.82 to -1.06)-2.88 (-3.25 to -2.50)
SecondaryChange From Baseline in Morning Stiffness Severity

Morning stiffness severity was assessed by a numeric rating-scale (NRS). Participants rated the severity of morning stiffness during the past week from 0 to 10 with 0 representing "not severe" and 10 "very severe". Negative values indicate improvement from baseline.

Time frame:
Baseline, Week 2, Week 4, Week 8, and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Morning Stiffness Severity
units on a scaleELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Week 2-1.76 (-2.54 to -0.98)-2.02 (-2.48 to -1.56)-0.91 (-1.47 to -0.35)-0.68 (-1.26 to -0.11)-0.59 (-1.15 to -0.04)-1.84 (-2.40 to -1.29)
Week 4-1.76 (-2.63 to -0.90)-2.71 (-3.22 to -2.21)-0.82 (-1.45 to -0.20)-0.83 (-1.47 to -0.19)-1.08 (-1.67 to -0.48)-2.51 (-3.13 to -1.90)
Week 8-1.67 (-2.56 to -0.77)-3.07 (-3.59 to -2.55)-1.30 (-1.94 to -0.65)-0.97 (-1.64 to -0.30)-1.50 (-2.11 to -0.88)-3.07 (-3.70 to -2.44)
Week 12-1.61 (-2.60 to -0.63)-3.23 (-3.81 to -2.65)-1.27 (-1.99 to -0.56)-1.30 (-2.06 to -0.55)-1.66 (-2.36 to -0.97)-3.36 (-4.06 to -2.67)
SecondaryPercentage of Participants Achieving Minimal Clinically Important Difference (MCID) in Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. The minimal clinically important difference (MCID) in HAQ-DI is defined as change from Baseline ≤ -0.22 for rheumatoid arthritis.

Time frame:
Baseline, Week 2, Week 4, Week 8, and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Minimal Clinically Important Difference (MCID) in Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)
percentage of participantsELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Week 252.6 (34.67 to 69.93)51.6 (41.33 to 61.76)36.6 (25.40 to 49.43)30.8 (20.20 to 43.84)36.6 (25.40 to 49.43)52.5 (39.77 to 64.91)
Week 468.4 (49.55 to 82.70)54.8 (44.46 to 64.81)34.1 (23.29 to 46.97)41.0 (29.07 to 54.15)53.7 (41.02 to 65.84)45.0 (32.79 to 57.84)
Week 852.6 (34.67 to 69.93)58.1 (47.63 to 67.82)51.2 (38.71 to 63.58)51.3 (38.47 to 63.93)36.6 (25.40 to 49.43)65.0 (52.01 to 76.09)
Week 1247.4 (30.07 to 65.33)58.1 (47.63 to 67.82)53.7 (41.02 to 65.84)43.6 (31.37 to 56.64)43.9 (31.93 to 56.63)55.0 (42.16 to 67.21)
SecondaryPercentage of Participants Achieving American College of Rheumatology/European League Against Rheumatism (EULAR) Boolean Remission

The EULAR Boolean-based definition of remission is as follows: at any time point, a participant must satisfy all of the following: tender joint count ≤1, swollen joint count ≤1, C-reactive protein ≤1 mg/dl and Patient Global Assessment (PGA) ≤1 (on a 0-10 scale).

Time frame:
Baseline, Week 2, Week 4, Week 8, and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology/European League Against Rheumatism (EULAR) Boolean Remission
percentage of participantsELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
Week 20 (0.00 to 12.46)1.6 (0.36 to 6.91)0 (0.00 to 6.19)0 (0.00 to 6.49)0 (0.00 to 6.19)0 (0.00 to 6.34)
Week 40 (0.00 to 12.46)6.5 (2.93 to 13.62)2.4 (0.55 to 10.22)0 (0.00 to 6.49)0 (0.00 to 6.19)2.5 (0.56 to 10.46)
Week 80 (0.00 to 12.46)6.5 (2.93 to 13.62)2.4 (0.55 to 10.22)5.1 (1.71 to 14.37)0 (0.00 to 6.19)12.5 (6.22 to 23.53)
Week 120 (0.00 to 12.46)11.3 (6.24 to 19.58)9.8 (4.46 to 20.04)2.6 (0.57 to 10.71)2.4 (0.55 to 10.22)10.0 (4.57 to 20.50)

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the first dose of study drug until 30 days after last study drug administration, up to 16 weeks. In addition, serious adverse events and protocol-related nonserious adverse events were collected from the time the participant signed the study-specific informed consent.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ELS Placebo/UPA Placebo0/19 (0%)1/19 (5.3%)10/19 (52.6%)
UPA 15 mg/ELS 60 mg0/62 (0%)0/62 (0%)7/62 (11.3%)
ELS 60 mg/UPA Placebo0/41 (0%)0/41 (0%)17/41 (41.5%)
ELS 20 mg/UPA Placebo0/39 (0%)2/39 (5.1%)10/39 (25.6%)
ELS 5 mg/UPA Placebo1/41 (2.4%)3/41 (7.3%)8/41 (19.5%)
UPA 15 mg/ELS Placebo0/40 (0%)0/40 (0%)9/40 (22.5%)
Most frequent serious events
Most frequent serious events
EventELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
PROSTATIC SPECIFIC ANTIGEN INCREASEDInvestigations1/190/620/410/390/410/40
CORONARY ARTERY DISEASECardiac disorders0/190/620/411/390/410/40
LUMBAR RADICULOPATHYNervous system disorders0/190/620/411/390/410/40
CARDIAC ARRESTCardiac disorders0/190/620/410/391/410/40
PYELONEPHRITISInfections and infestations0/190/620/410/391/410/40
CLAVICLE FRACTUREInjury, poisoning and procedural complications0/190/620/410/391/410/40
RIB FRACTUREInjury, poisoning and procedural complications0/190/620/410/391/410/40
ROAD TRAFFIC ACCIDENTInjury, poisoning and procedural complications0/190/620/410/391/410/40
Most frequent other events
Showing 10 of 20
Most frequent other events
EventELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS Placebo
RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders2/190/623/413/393/410/40
URINARY TRACT INFECTIONInfections and infestations0/190/624/412/392/413/40
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations1/194/622/413/392/412/40
DIARRHOEAGastrointestinal disorders0/190/623/410/390/410/40
PERIPHERAL SWELLINGGeneral disorders1/190/621/410/390/410/40
BRONCHITISInfections and infestations1/190/621/410/391/410/40
SINUSITISInfections and infestations1/190/621/410/390/410/40
TOOTH INFECTIONInfections and infestations1/190/620/411/390/411/40
ANIMAL BITEInjury, poisoning and procedural complications1/190/620/410/390/410/40
BLOOD GLUCOSE INCREASEDInvestigations1/190/620/410/390/410/40

Baseline characteristics

Full Analysis Set: all randomized participants who received at least 1 dose of randomized study drug

Age, Continuous
Age, Continuous(years)ELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS PlaceboTotal
Mean57.6 ± 9.1256.2 ± 12.8259.2 ± 11.1159.7 ± 10.9558.1 ± 11.0157.7 ± 10.6058.0 ± 11.27
Sex: Female, Male
Sex: Female, Male(Participants)ELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS PlaceboTotal
Female174836353335204
Male214548538
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ELS Placebo/UPA PlaceboUPA 15 mg/ELS 60 mgELS 60 mg/UPA PlaceboELS 20 mg/UPA PlaceboELS 5 mg/UPA PlaceboUPA 15 mg/ELS PlaceboTotal
White195836353537220
Black or African American03443317
American Indian or Alaska Native0010102
Native Hawaiian or Other Pacific Islander0000000
Asian0100102
Multiple0000101
08

Study locations

115 sites
  • Rheum Assoc of North Alabama /ID# 167382
    Huntsville, Alabama 35801, United States
  • AZ Arthritis & Rheum Research /ID# 167446
    Mesa, Arizona 85210, United States
  • SunValley Arthritis Center, Lt /ID# 213073
    Peoria, Arizona 85381, United States
  • AZ Arthritis and Rheum Researc /ID# 167448
    Phoenix, Arizona 85032, United States
  • St. Joseph Heritage Healthcare /ID# 167379
    Fullerton, California 92835, United States
  • Purushotham, Akther & Roshan K /ID# 168121
    La Mesa, California 91942, United States
  • Valerius Medical Group /ID# 168123
    Los Alamitos, California 90720, United States
  • Sierra Rheumatology /ID# 167976
    Roseville, California 95661, United States
  • Rheumatology Center of San Diego /ID# 170690
    San Diego, California 92128-2549, United States
  • Iraj Sabahi Research, Inc /ID# 201923
    Turlock, California 95382-2007, United States
  • Inland Rheum Clin Trials Inc. /ID# 167459
    Upland, California 91786, United States
  • Medvin Clinical Research /ID# 205731
    Whittier, California 90606, United States
  • Rheumatology Consultants of De /ID# 208238
    Lewes, Delaware 19958, United States
  • Bay Area Arthritis and Osteo /ID# 208111
    Brandon, Florida 33511, United States
  • Clinical Res of West FL, Inc. /ID# 167462
    Clearwater, Florida 33765, United States
  • Omega Research Maitland, LLC /ID# 167376
    DeBary, Florida 32713-2260, United States
  • Riverside Clinical Research /ID# 167982
    Edgewater, Florida 32132, United States
  • Lakes Research, LLC /ID# 170660
    Miami, Florida 33014, United States
  • Kendall South Medical Center, Inc. /ID# 206857
    Miami, Florida 33185-5948, United States
  • Medallion Clinical Research Institute, LLC /ID# 201710
    Naples, Florida 34102, United States
  • Rheum Assoc of Central FL /ID# 170858
    Orlando, Florida 32806, United States
  • HMD Research LLC /ID# 208381
    Orlando, Florida 32819, United States
  • International Medical Research - Ormond /ID# 170864
    Ormond Beach, Florida 32174, United States
  • Millennium Research /ID# 167453
    Ormond Beach, Florida 32174, United States
  • Arthritis Center, Inc. /ID# 170695
    Palm Harbor, Florida 34684, United States
  • Integral Rheumatology & Immunology Specialists /ID# 206724
    Plantation, Florida 33324, United States
  • BayCare Medical Group /ID# 170860
    Saint Petersburg, Florida 33705, United States
  • St. Anthony Comprehensive Rese /ID# 170668
    Saint Petersburg, Florida 33705, United States
  • Clinical Research of West Florida, Inc /ID# 169099
    Tampa, Florida 33606-1246, United States
  • ForCare Clinical Research /ID# 206280
    Tampa, Florida 33613-1244, United States
  • Florida Medical Clinic /ID# 206279
    Zephyrhills, Florida 33542, United States
  • Institute of Arthritis Researc /ID# 170694
    Idaho Falls, Idaho 83404, United States
  • Great Lakes Clinical Trials /ID# 167471
    Chicago, Illinois 60640, United States
  • Clinical Investigation Specialists - Skokie /ID# 167468
    Skokie, Illinois 60076, United States
  • Deerbrook Medical Associates /ID# 207098
    Vernon Hills, Illinois 60061, United States
  • PRN of Kansas /ID# 167985
    Wichita, Kansas 67205, United States
  • The Arthritis & Diabetes Clinic, Inc. /ID# 170682
    Monroe, Louisiana 71203, United States
  • Mansfield Health Center /ID# 167372
    Mansfield, Massachusetts 02048, United States
  • Advanced Clinical Care /ID# 167367
    Worcester, Massachusetts 01605, United States
  • June DO, PC /ID# 170670
    Lansing, Michigan 48910, United States
  • Beals Instititute /ID# 170658
    Lansing, Michigan 48917, United States
  • Arthritis Associates /ID# 209075
    Hattiesburg, Mississippi 39402, United States
  • North Mississippi Med Clinics /ID# 167377
    Tupelo, Mississippi 38801, United States
  • Clayton Medical Associates dba Saint Louis Rheumatology /ID# 170650
    Saint Louis, Missouri 63119-3845, United States
  • Physician Research Collaboration, LLC /ID# 200480
    Lincoln, Nebraska 68516, United States
  • Dhmc /Id# 167476
    Lebanon, New Hampshire 03756, United States
  • Ocean Rheumatology /ID# 170673
    Toms River, New Jersey 08755, United States
  • Arthritis and Osteo Assoc /ID# 167443
    Las Cruces, New Mexico 88011, United States
  • DJL Clinical Research, PLLC /ID# 167374
    Charlotte, North Carolina 28210-8508, United States
  • EmergeOrtho, P.A. /ID# 209154
    Durham, North Carolina 27704, United States
  • Cape Fear Arthritis Care /ID# 167413
    Leland, North Carolina 28451, United States
  • New Horizons Clinical Research /ID# 170862
    Blue Ash, Ohio 45242-3763, United States
  • Marietta Memorial Hospital /ID# 210968
    Marietta, Ohio 45750-1635, United States
  • STAT Research, Inc. /ID# 200485
    Vandalia, Ohio 45377-9464, United States
  • Health Research of Oklahoma /ID# 167370
    Oklahoma City, Oklahoma 73103-2400, United States
  • Clinical Research Ctr Reading /ID# 170708
    Wyomissing, Pennsylvania 19610, United States
  • West Tennessee Research Inst /ID# 167366
    Jackson, Tennessee 38305, United States
  • Nashville Arthritis and Rheumatology /ID# 206699
    Nashville, Tennessee 37203, United States
  • Amarillo Ctr for Clin Research /ID# 200484
    Amarillo, Texas 79124, United States
  • Tekton Research, Inc. /ID# 167475
    Austin, Texas 78745, United States
  • Trinity Universal Res Assoc /ID# 209252
    Carrollton, Texas 75007, United States
  • Arth and Osteo Clin Brazo Valley /ID# 209401
    College Station, Texas 77845, United States
  • Metroplex Clinical Research /ID# 167458
    Dallas, Texas 75231, United States
  • Rheumatic Disease Clin Res Ctr /ID# 167474
    Houston, Texas 77004, United States
  • Rheumatology Clinic of Houston /ID# 203689
    Houston, Texas 77065, United States
  • Accurate Clinical Research /ID# 207059
    Houston, Texas 77089, United States
  • West Texas Clinical Research /ID# 205732
    Lubbock, Texas 79410-1198, United States
  • SW Rheumatology Res. LLC /ID# 167383
    Mesquite, Texas 75150, United States
  • Trinity Universal Research Association /ID# 209253
    Plano, Texas 75024-5283, United States
  • Sun Research Institute /ID# 170667
    San Antonio, Texas 78215, United States
  • Accurate Clinical Management /ID# 200481
    San Antonio, Texas 78229, United States
  • DM Clinical Research /ID# 167444
    Tomball, Texas 77375, United States
  • Arthritis & Osteoporosis Clinic /ID# 167407
    Waco, Texas 76710, United States
  • Tidewater Physicians Medical Center /ID# 210884
    Newport News, Virginia 23606-4434, United States
  • Western Washington Arthritis C /ID# 205821
    Bothell, Washington 98021, United States
  • Arthritis Northwest, PLLC /ID# 200479
    Spokane, Washington 99204, United States
  • Rheumatology and Pulmonary cli /ID# 170863
    Beckley, West Virginia 25801, United States
  • Aurora Rheumatology and Immunotherapy Center /ID# 167385
    Franklin, Wisconsin 53132, United States
  • CUB Hospital Erasme /ID# 201965
    Brussels, Bruxelles-Capitale 1070, Belgium
  • Cliniques Universitaires Saint Luc /ID# 201756
    Woluwe-Saint-Lambert, Bruxelles-Capitale 1200, Belgium
  • UZ Ghent /ID# 201757
    Ghent, Oost-Vlaanderen 9000, Belgium
  • UZ Leuven /ID# 201927
    Leuven, 3000, Belgium
  • Rheumatology Research Assoc /ID# 207299
    Edmonton, Alberta T5M 0H4, Canada
  • Manitoba Clinic /ID# 202126
    Winnipeg, Manitoba R3A 1M3, Canada
  • CIADS Research Co Ltd /ID# 202125
    Winnipeg, Manitoba R3N 0K6, Canada
  • Credit Valley Rheumatology /ID# 202124
    Mississauga, Ontario L5M 2V8, Canada
  • Mount Sinai Hosp.-Toronto /ID# 202652
    Toronto, Ontario M5G 1X5, Canada
  • Dr. Latha Naik /ID# 212972
    Saskatoon, Saskatchewan S7K 3H3, Canada
  • Revmatolog s.r.o. /ID# 202610
    Jihlava 1, Jihlava 586 01, Czechia
  • Revmatologicky ustav Praha /ID# 202142
    Prague 2, Praha 2 128 00, Czechia
  • Revmatologie MUDr. Klara Sirova /ID# 205185
    Ostrava, 702 00, Czechia
  • CCR Czech a.s /ID# 202144
    Pardubice, 530 02, Czechia
  • CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 202439
    Miskolc, Borsod-Abauj-Zemplen 3529, Hungary
  • Szabolcs-Szatmar-Bereg Megyei Korhazak & Egyetemi Oktatokorhaz /ID# 202441
    Nyíregyháza, Szabolcs-Szatmar-Bereg 4400, Hungary
  • Revita Reumatologiai Rendelo /ID# 202438
    Budapest, 1027, Hungary
  • CMED Rehabilitacios es Diagnosztikai Kozpont /ID# 205804
    Szekesfehervar, 8000, Hungary
  • Vital Medical Center Orvosi-es Fogaszati Kozpont /ID# 202437
    Veszprem, 8200, Hungary
  • Malopolskie Centrum Kliniczne /ID# 206473
    Cracow, Malopolskie 30-149, Poland
  • McBk Sc /Id# 212575
    Grodzisk Mazowiecki, Mazowieckie 05-825, Poland
  • NBR Polska /ID# 206476
    Warsaw, Mazowieckie 00-465, Poland

Showing the first 100 of 115 sites across 9 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Mar 2020, 17 months.

Results were first posted in May 2021, 1 year 1 month after primary completion.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 17 months is close to that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2018
First posted
Sep 25, 2018
StartActual
Oct 8, 2018
Primary completionActual
Mar 26, 2020
CompletionActual
Mar 26, 2020
Results first posted
May 3, 2021
Last update
May 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03682705
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 25, 2018
Start date
Oct 8, 2018
Primary completion
Mar 26, 2020
Completion
Mar 26, 2020
Results posted
May 3, 2021
Last update
May 3, 2021

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elsubrutinib · Upadacitinib

Start the discussion